EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients

Mingshu Sun, Zhaohui Lyu, Can Wang, Yan Li, Dongbao Zhao, Xingwu Ran iD, Haibing Chen iD, Benli Su, Xiangyun Chang, Ping Liu, Dewen Yan, Xiuyun Jiang und 19 weitere

International Journal of Rheumatic Diseases · 2025-07 · 28 (7)

DOI: 10.1111/1756-185x.70375 ↗

Kurz gefasst

Leitlinie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 21.07.2025. Verfasst von Mingshu Sun und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Xiang'an Hospital of Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Hyperuricemia, Gout, Gout Suppressants. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Projects of International Cooperation and Exchanges NSFC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2018, the Chinese Society of Endocrinology developed the “Chinese guideline for diagnosis and treatment of hyperuricemia and gout (2019)”. Over the past 5 years, clinical and experimental research has expanded our knowledge of gout, resulting in novel diagnostic and therapeutic approaches. This update, prompted by new clinical challenges and gaps in evidence, aims to refine the 2019 guidelines.

Methods

The working group formulated clinical questions based on a nationwide questionnaire survey, and the expert panel evaluated new evidence addressing these questions from January 2019 to March 2025. The guideline development followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, adhering to internationally recognized protocols for clinical practice guideline development.

Results

The update includes 26 recommendations addressing 10 clinical questions related to urate‐lowering therapy (ULT) for asymptomatic hyperuricemia and reproductive populations, anti‐inflammatory treatments, urine alkalinization, dietary advice, and gout diagnosis in patients without a record of hyperuricemia and gout flare predictions in patients with asymptomatic hyperuricemia and intermittent gout. It recommends febuxostat as a first‐line ULT for asymptomatic hyperuricemia and using it with caution during pregnancy and lactation. ULT should be customized according to the pathophysiologic type of hyperuricemia. Chronic gout management includes maintaining serum urate levels between 180 and 300 μmol/L and prolonged glucocorticoid tapering in combination with colchicine. Alkalinization with citrate is preferred over sodium bicarbonate for patients with urine pH < 6.0. Novel biomarkers for predicting gout flares are proposed for high‐risk populations.

Conclusions

These updated guidelines incorporate expert consensus and evidence to provide refined strategies for the diagnosis, prevention, and treatment of hyperuricemia and gout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaGoutGout SuppressantsHumansChinaUric AcidConsensusFemaleBiomarkers

Stichwörter der Autor:innen

diagnosisgoutguidelinehyperuricemiamanagementprediction

Substanzen

Gout SuppressantsUric AcidBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Xiang'an Hospital of Xiamen University, Xiamen, China.
  • Department of Endocrinology, the First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Rheumatology, the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai, China.
  • Department of Endocrinology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xingwu Ran, Haibing Chen, Ying Chen, Jidong Cheng, Huiyong Yin, Chao Liu, Yaolong Chen, Jiajun Zhao

Förderung

  • National Key Research and Development Program of China
  • Projects of International Cooperation and Exchanges NSFC

Zitieren

APA

Sun, M., Lyu, Z., Wang, C., Li, Y., Zhao, D., Ran, X., Chen, H., Su, B., Chang, X., Liu, P., Yan, D., Jiang, X., Chen, K., Shao, J., Teng, X., Yao, Y., Li, Y., Chen, Y., Cheng, J., …, & Zhao, J. (2025). 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. International Journal of Rheumatic Diseases, 28(7). https://doi.org/10.1111/1756-185x.70375

Vancouver

Sun M, Lyu Z, Wang C, Li Y, Zhao D, Ran X, et al. 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. International Journal of Rheumatic Diseases. 2025;28(7). doi:10.1111/1756-185x.70375

BibTeX
@article{Sun2025,
  author = {Sun, Mingshu and Lyu, Zhaohui and Wang, Can and Li, Yan and Zhao, Dongbao and Ran, Xingwu and Chen, Haibing and Su, Benli and Chang, Xiangyun and Liu, Ping and Yan, Dewen and Jiang, Xiuyun and Chen, Kang and Shao, Jiaqing and Teng, Xiaochun and Yao, Yongli and Li, Yuming and Chen, Ying and Cheng, Jidong and Cheng, Zhifeng and Liu, Zhen and Liu, Fengjing and Li, Xinyu and Yin, Huiyong and Liu, Chao and Lin, Hsiao-Yi and Chen, Yaolong and Tsai, Wen-Chan and Yip, Ronald M L and Li, Changgui and Zhao, Jiajun},
  title = {2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  volume = {28},
  number = {7},
  doi = {10.1111/1756-185x.70375}
}
Kostenlos starten →